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Abstract: The cattle tick Rhipicephalus microplus is one of the most important ectoparasites causing
significant economic losses for the cattle industry. The major tool of control is reducing the number of
ticks, applying acaricides in cattle. However, overuse has led to selection of resistant populations of
R. microplus to most of these products, some even to more than one active principle. Thus, exploration
for new molecules with acaricidal activity in R. microplus has become necessary. Triosephosphate
isomerase (TIM) is an essential enzyme in R. microplus metabolism and could be an interesting target
for the development of new methods for tick control. In this work, we screened 227 compounds,
from our in-house chemo-library, against TIM from R. microplus. Four compounds (50, 98, 14, and 161)
selectively inhibited this enzyme with IC50 values between 25 and 50 µM. They were also able to
diminish cellular viability of BME26 embryonic cells by more than 50% at 50 µM. A molecular docking
study showed that the compounds bind in different regions of the protein; compound 14 interacts
with the dimer interface. Furthermore, compound 14 affected the survival of partially engorged
females, fed artificially, using the capillary technique. This molecule is simple, easy to produce,
and important biological data—including toxicological information—are available for it. Our results
imply a promising role for compound 14 as a prototype for development of a new acaricidal involving
selective TIM inhibition.
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1. Introduction
The cattle tick Rhipicephalus microplus is the most significant ectoparasite in tropical and
sub-tropical regions, with associated economic losses estimated at US $22–30 billion annually [1].
Its bite causes damage to the skin, promoting local inflammation that harms the animal leather
industry. It also affects animal weight gain and, consequently, milk and meat production [2]. It is
the most important vector for cattle disease agents, such as Babesia spp. and Anaplasma spp. [3].
The application of synthetic acaricides is the main method used to control these ectoparasites [4].
However, the continuous and indiscriminate use of acaricides has led to chemico-resistant ticks [5,6].
In addition, these chemicals are polluting the environment and animal byproducts, resulting in new
restriction polices for the exportation of these animal byproducts. In several countries, resistance
to most acaricides has been confirmed, which represent a worldwide drawback for successful tick
control [7–9]. R. microplus resistance to various acaricides has appeared in chronological sequence,
and global spread of resistance to acaricides has become a serious challenge for the livestock
industry [10]. Thus, the exploration of new molecules, having novel mechanisms of action with
acaricidal activity for R. microplus, is still necessary.
There are some explorations on new molecular targets as antigens for tick control [11].
One example is the observation that RNAi silencing of AamAV422, an Amblyomma americanum salivary
gland protein, reduces the tick blood meal [12]. Another example is the demonstration that monoclonal
antibodies against triosephosphate isomerase (TIM) can inhibit its enzymatic activity and cellular
proliferation of the embryonic tick cell line (BME26) [13].
TIM is a glycolytic and gluconeogenesis enzyme that catalyzes glyceraldehyde 3-phosphate and
dihydroxyacetone phosphate interconversion. Several publications reported the potential of TIM for
drug development against various parasites that cause human diseases, such as Plasmodium falciparum,
Trypanosoma cruzi, Trypanosoma brucei, Fasciola hepatica, and Giardia lamblia [14–16]. In particular,
our group reported the first study using this concept for ectoparasites, and showed that some cysteine
residues of R. microplus TIM (RmTIM) could be a target for drug design [17]. Although the structural
similarity of this enzyme is highly conserved between species, it is possible to obtain selective inhibitors,
if they act at the interface of the enzyme, since this part of the enzyme is poorly conserved between
species [18].
Nowadays, organophosphates are the major chemical acaricides in use (with high environmental
impact), which includes pyrethroids, macrocyclic lactones, amidines (like amitraz), fipronil,
and fluazuron [19,20]. These can be administered in different forms, such as dip concentrates, spraying,
injection, or pour-on treatments [4,21]. Amitraz and Fluazuron were discovered by rational design,
in 1973 and 1990 respectively, which are some of the most useful drugs against R. microplus [22,23].
Ivermectin (macrocyclic lactones) and some pyrethroids are also very useful drugs, but acaricide
resistance threatens their utility [24]. Acaricide discovery is not a very active field of work in academic
institutions. From approximately 200 publications in the last 5 years, most of them describe extracts
of natural products with acaricidal activity, but with no structural characterization of the constituent
compounds [25–28].
By contrast, this work takes a typical medicinal-chemistry approach to find new bioactive
molecules with potential acaricidal applications. Based on our experience with parasiticides and
enzymatic inhibitors, we screened synthetic molecules from our in-house library, in order to find
inhibitors of RmTIM [29,30]. The best inhibitors were identified, and some of these compounds were
selected to carry out in vitro assays with R. microplus to find new molecules as candidates for future
acaricide development.
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2. Materials and Methods
2.1. Tick Strains
The Porto Alegre ticks strain (POA) R. microplus (Acarina, Ixodidae), were obtained by
experimental infestation on bovines (ethical code number 07/2012). This strain was originally collected
in the district of Porto Alegre, state of Rio Grande do Sul (Brazil), from a farm without a history
of acaricide use and was established in the Faculdade de Veterinária, Universidade Federal do Rio
Grande do Sul (UFRGS). It has been maintained under standard laboratory conditions in the absence
of acaricide exposure for multiple generations. Ticks are free of parasites, and were reared on bovines
obtained from a tick-free area [31]. The partially engorged female ticks were removed from cattle and
used for further experiments.
2.2. In Silico Analyses
The DNA sequence analysis, amino acid predictions, and sequence alignments of TIMs
from different organisms were performed using the BioEdit (version 7.2.5) [32] and GeneDoc
software. (version 5.10) [33]. For phylogenetic analysis, an uprooted neighbor-joining phylogenetic
tree was created using the MEGA software (version 6.0) [34]. Bootstrap support was assessed
using 1000 replicates. The GenBank accession numbers for TIM used in our analyses were:
Bos taurus (NP_001013607), Amblyomma cajennense (JAC21035); Amblyomma maculatum (AEO34689),
Amblyomma parvum (JAC25576), Amblyomma triste (JAC33162), Rhipicephalus microplus (ABK76308),
Hyalomma excavatum (JAP67226), Ixodes ricinus (JAA69917), Ixodes scapularis (XP_002411305),
and Rhipicephalus pulchellus (JAA59214).
2.3. Cloning of the RmTIM cDNA in the pET System, Growth of Cells, and Protein Expression
We amplified the RmTIM open read frame sequence using a plasmid construction obtained by
Moraes et al. 2011 as a template for subsequent cloning in the pET3a-HisTEVp plasmid [35]. The 750 bp
PCR fragment was generated with the primers forward (FOR) (GGGAATTCCATATGGCCGCAC)
and reverse (REV) (CGGGATCCGCTAACCCTGCA), subsequently digested with NdeI and BamHI,
purified, and cloned directionally in the pET-3a-HisTEVp plasmid. Nucleotide sequence analysis of
the clones was performed to confirm the identity of the amplicon and the inserted reading frame.
For expression, BL21 CodonPlus E. coli cells were transformed with the pET3a-HisTEVp-RmTIM
plasmid. Transformed cells were grown overnight at 37 ◦C in Terrific Broth supplemented with
100 µg/mL ampicillin and 34 µg/mL chloramphenicol. When cultures reached an A600 of 0.6–0.8,
1 mM isopropyl α-D-thiogalactopyranoside was added, and cells were incubated overnight for the
expression of TIM.
2.4. Purification of RmTIM
Cells were harvested by centrifugation and suspended in lysis buffer containing 50 mM NaH2PO4,
300 mM NaCl, and 10 mM imidazole, pH 8.0. Cells were maintained at 4 ◦C, disrupted by sonication
and centrifuged at 100,000× g for 1 h. The supernatant was added to a 5 mL HisTrap HP column
(GE Healthcare, Chicago, IL, USA) and eluted with an imidazole gradient (0–1000 mM). The eluted
protein was added to a HiPrep 26/10 Desalting column (GE Healthcare, Piscataway, NJ, USA) in
50 mM Tris HCl, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol (DTT), pH 8.0
(a buffer favoring Tobacco Etch Virus protease (TEVp) activity). The eluted enzyme was incubated
overnight at 30 ◦C with TEVp at a ratio of 20 RmTIM/1 TEVp (w/w). The digested proteins were then
added to a Hi Prep 26/10 Desalting column (GE Healthcare) in a buffer containing 50 mM NaH2PO4,
300 mM NaCl, and 10 mM imidazole, pH 8.0, and the eluted sample separated in the HisTrap HP
column (GE Healthcare). This last step removes the (His)6-tag-TEVpV from the RmTIM. The enzyme
was concentrated to 6 mg/mL with Amicon Ultra filters with 30,000 MWCO (Millipore Co., Bedford,
MA, USA), and dialyzed overnight in 100 mM triethanolamine (TEA), 1 mM EDTA, and 1 mM DTT.
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The purification steps were monitored by SDS-PAGE gels containing 16% acrylamide, and stained
with Coomassie blue.
2.5. Homo sapiens TIM and Rabbit TIM
Homo sapiens TIM (HsTIM) was expressed in E. coli, and purified as described in the literature [35].
Rabbit TIM (RbTIM) was obtained commercially from Sigma-Aldrich (Saint Louis, MO, USA).
Both enzymes were used in further experiments to test specificity. For inhibition experiments, enzymes
were dialyzed extensively against 100 mM triethanolamine and 10 mM EDTA (pH 7.4). Protein
concentrations were determined from their absorbance at 280 nm using an extinction coefficient of
34,950 M−1 cm−1, calculated according to the method of Pace et al. [36].
2.6. Triosephosphate Isomerase Activity Assays
TIM activity was determined by measuring the amount of D-glyceraldehyde 3-phosphate
converted to dihydroxyacetone phosphate. The reaction mixture contained purified RmTIM (6 ng
of protein) in 100 mM TEA, 10 mM EDTA, 1 mM D-glyceraldehyde 3-phosphate, 0.2 mM NADH,
and 0.9 units of α-glycerol phosphate dehydrogenase (pH 7.4). Activity was determined following
NADH consumption at 340 nm as a function of time, in a HP8452 spectrophotometer (Agilent
Technologies, Palo Alto, CA, USA) with a multicell attachment, with a controlled temperature of
25 ◦C. The assay was made in a traditional cuvette with a final volume of 1000 µL which contained
927 µL of TE Buffer, 50 µL of D-glyceraldeyde-3-phosphate (20 mM), 20 µL of α-glycerol phosphate
dehydrogenase (45 U/mL), 2 µL of NADH (100 mM), and 1 µL of TIM (6 mg/mL) [17].
2.7. Inhibition Screening and Compound Library
The inhibition was carried out under the same conditions as the activity assays. Before the
determination of the activity, the selected compounds and TIM were incubated at 25 ◦C for 2 h.
The selected compound was dissolved in DMSO and diluted to 10% (v/v) of DMSO in the incubation
mixture. The 227 molecules were chosen from an in-house library, with diverse chemical structures.
Based on sequence similarities found in the alignment of different TIMs, in particular, between the
TIMs from T. cruzi and R. microplus, we chose molecules that had previously shown either antiparasitic
activity or inhibition of TIM [29,30]. In a first round of screening, the compounds were assayed
at 100 µM. A compound was considered active if the enzymatic inhibition was higher than 50%.
The active compound was assayed at different concentrations to determine the IC50 value. The IC50
was defined as the drug concentration at which 50% of the initial velocity was determined, relative to
the control (no drug added), and analyzed using OriginLab8.5® sigmoidal regression (% of enzymatic
activity vs logarithm of the compound concentration). All assays were done in triplicate, and the
average error for each measurement did not exceed 10%.
2.8. Ligand–Protein Molecular Docking
The geometrical structures of compounds 50, 98, and 14 were fully optimized in aqueous solution
at the PM6 semi-empirical level using the IEF-PCM continuum model with Bondi atomic radii.
For molecular docking studies, the crystallographic structure of RmTIM (PDB ID 3TH6) was used [17].
Docking calculations were carried out with Autodock 4.2 using the implemented empirical free
energy function and the Lamarckian genetic algorithm. The AutoDockTools package was employed to
generate the docking input files and to analyze the docking results. Gasteiger–Marsili charges were
used for both proteins and ligands. Since the location of the compounds in the enzyme was unknown,
a grid map with 124 × 126 × 126 points and a grid-point spacing of 0.6 Å was applied in order to
explore the entire protein surface. The maps were centered on the macromolecule. Each docking
consisted of 50 independent runs, with an initial population of 150 individuals, a maximum number
of 2.5 × 105 energy evaluations, and a maximum number of 27,000 generations. Default values were
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used for the remaining parameters. Results differing by less than 2.0 Å in root-square deviation were
grouped into the same cluster.
2.9. MTT Viability Assay
R. microplus embryonic cell line BME26 suspension was seeded into 24-well plates (5 ×
105 cells/well) to a final volume of 500 µL in complete medium, and allowed to attach. After 24 h
incubation at 34 ◦C, chemical inhibitors were added at the final concentrations indicated, and 0.05%
DMSO was used in negative control wells. After 24 h of treatment, 50 µL MTT prepared in serum-free
medium (5 mg/mL) was added to each well. Media were completely discarded after 2 additional
hours of incubation, and 1 mL of acid-isopropyl alcohol (0.15% HCl in isopropyl alcohol) was added to
dissolve the formazan crystals. The mixture was transferred to 1.5 mL tubes, centrifuged at 6000× g for
15 min, and the clear supernatant collected in new tubes for absorbance measurement at 570 nm using
quartz cuvettes in an UVmini-1240 UV–vis spectrophotometer (Shimadzu, Japan). Unless otherwise
stated, the absorbance values of the control treatment were used for normalization (100% viability) [37].
2.10. Effect of Compounds on BME26 Cell Cultures
The Rhipicephalus microplus embryonic cell line BME26 was maintained in Leibovitz’s culture
medium supplemented with amino acids, glucose, mineral salts, and vitamins [38]. For the tests,
BME26 cells were adjusted to a concentration of 106/mL, and aliquots of 0.1 mL were added to 24-well
microtiter plates and incubated for 24 h at 34 ◦C. Then cells were incubated for 24 h with 25, 50,
or 100 µM of compounds 50, 98, and 14.
2.11. Effect of Compounds on BME26 Morphology
BME26 cells (5 × 105 cells/well) were plated on glass coverslips (Corning® Costar®, Cambridge,
MA, USA) in 24-well plates, and incubated in complete medium to attach at 34 ◦C for 24 h. Chemical
inhibitors were added at the final concentrations indicated, and 0.05% DMSO was used in negative
control wells. After 24 h of treatment, the cells were washed with 0.15 M NaCl, 10 mM sodium
phosphate, pH 7.2 (PBS), and immediately fixed on a buffered (PBS) formaldehyde 4% solution for
15 min at room temperature (RT). The cells were then incubated for 20 min (RT) with 200 µL of
a solution containing the nuclear marker DAPI (4′,6-diamidino-2-phenylindole, dihydrochloride,
molecular Probes, D1306-1 µg/mL), and 1 µL of the F-actin probe phalloidin (Alexa Fluor® 555,
Molecular Probes, A34055-300 units). The cells were visualized using a Leica DMI4000 inverted
fluorescent microscope equipped with two A4 (DAPI) filter cubes and N2.1 (Phalloidin). Pictures were
obtained with a DFC365 FX camera, and images were mounted into a single file with the help of Adobe
Photoshop (CC19.0).
2.12. Adults Immersion Test
Each group of 15 fully engorged females was immersed in 50 mL tubes containing 40 mL of
compound 14 at different concentrations (500 and 2000 ppm) for five minutes. Two negative control
groups were used, one in PBS and another in DMSO 10%. After immersion, the fully engorged
females were dried on absorbent paper. They were then placed in 100 mm disposable Petri dishes,
identified, and taken to the Bio-Oxygen Demand chamber, where they were kept at 27 ◦C ± 1 ◦C
and relative humidity of 80% ± 5% for 21 days. Females that did not lay eggs were considered dead.
The eggs were weighed and transferred to disposable plastic syringes closed with hydrophilic cotton
and returned to the Bio-Oxygen Demand under the same conditions, until the larvae had hatched.
The efficacy of compound on R. microplus physiology was calculated based on the weight of the fully
engorged females, eggs, larvae, and percentage of hatching, according to Drummond et al. 1973 [39].
The statistical analyses were performed using one-way ANOVA followed by Tukey’s test. p values
around 0.05 were considered statistically significant.
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2.13. Effect of Administration of Inhibitor 14 in Partially Engorged Female Ticks
Partially engorged female ticks (obtained as described in Section 2.12) after 30 days of feeding,
weighing 30–60 mg, were collected from bovines and fixed with double-sided tape in a polystyrene
surface, and fed with bovine blood by capillarity for 28 h [40–42]. During the feeding process, 2 µL of
the compound (at 1 mM in DMSO) was injected in the lower quadrant of the ventral surface, using a
Hamilton syringe with a 0.460 mm needle gauge (the control groups were inoculated with DMSO).
Female feeding was performed at 28 ◦C in 85% humidity. All parameters were analyzed after feeding.
2.14. Effects of RmTIM Inhibitor 14 on Tick Physiology
The effects of RmTIM inhibitor 14 were evaluated by inoculation and immersion tests. The ticks
were handled as described in Sections 2.12 and 2.13. The parameters analyzed after that were
total egg weight, total larval weight, eclosion rate, and mortality (percentage of dead females).
For these terms, the females that did not lay eggs were considered dead. All statistical analyses were
performed using one-way ANOVA followed by Tukey’s test. p values around 0.05 were considered
statistically significant.
2.15. Oral Acute Toxicology in Mice
The in vivo LD50 for compound 14 was determined following the guidelines described by
Organization for Economic Co-operation and Development O.E.C.D. [43]. Briefly, healthy young
adult male mice (strain B6D2F1, 60 days old, 25–30 g) were used in this study. Initially, the compounds
used in our study were administered at a dose of 2000 mg/kg, by means of an orogastric canula, to a
first animal. This animal was fasted, maintained, and observed during 14 days. Depending on the
results after 48 h, another animal received a new dose, if the original animal survived these 48 h. If not,
the dose was reduced to 14 of the initial dose and administered, and the new animal was included in
the test. The procedure was repeated until the LD50 was determined. Every experimental protocol
with animal were previously approved by local ethics committee in animal experimentation [44].
3. Results
3.1. Sequence Analyses
The deduced amino acid sequence of R. microplus TIM had high similarity with other tick and
Bos taurus TIM sequences. Interestingly, remarkable differences in the number of cysteine residues
were observed. There are five cysteine residues that occur in almost all TIMs from ticks, but are
not present in B. taurus TIM (natural host for R. microplus) (Figure S1 in supporting information).
A phylogenetic analysis of TIMs from ticks was constructed based on their amino acid sequences
(Figure 1). The phylogenetic tree revealed two clades for the tick enzymes: one clade includes
R. microplus and Amblyomma spp. TIMs, and another clade formed by Ixodes spp. TIMs. As expected,
B. taurus TIM belongs to a well-separated clade.
3.2. Chemical Structure Leads Used in a Primary In Vitro Screening
The molecules used in this work were chosen from an in-house chemo-library of a thousand
compounds that have a structure–activity relationship related to trypanosomicidal and TIM-inhibition
activities. Two hundred and twenty seven compounds were selected based on their previously reported
activity against other parasites. We chose molecules with diverse chemical structures from different
families of compounds, including benzofuroxans, benzimidazoles, thiadiazines, hydrazide derivatives,
thiazolylidenehydrazines, flavonoids, furoxans, phenazines, thiadiazoles, indazoles, quinoxalines,
and triazines, among others (Figure 2).
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We chose 227 molecules with diverse chemotypes from different families of compounds including
benzofuroxans, benzimidazoles, thiadiazines, hydrazide derivatives, thiazolylidenehydrazines,
flavonoids, furoxans, phenazin s, thiadiazoles, indazoles, q inoxalines, triazines, as well as other
diverse structures. a Compounds are numbered according to Table S1 shown in the Supplementary
Material. b R groups correspond to different structural moieties.
3.3. In Vitro Inhibition at Recombinant Enzymes
Initially, a primary in vitro scr ening with 227 compounds at a concentration of 100 µM was
performed to find specific RmTIM inhibitors (all of these results are in Table S1). Sixteen new hits were
identified as new candidates to become inhibitors (an inhibition of more than 50% of RmTIM activity
at 100 µM). We observed that 7% of the compounds tested were active. Compounds 70, 99, 134, 136,
146, and 179 were poorly active (IC50 ~ 100 µM). Compounds 39, 52, 62, 81, 222, and 224 had medium
activity (IC50 between 50 µM and 100 µM). Four compounds showed higher ranges of inhibition (IC50
lower than 50 µM). These were compounds 14 (IC50 = 49 µM), 50 IC50 = 50 µM), 98 IC50 = 50 µM),
and 161 (IC50 = 25 µM). Subsequently, it was confirmed that these compounds had no considerable
inhibition activity for mammalian TIMs (rabbit and human) (Table 1 and Figure 3).
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Table 1. IC50 values of the most active compounds against RmTIM and percentages of inhibition for
human (HmTIM) and rabbit (RbTIM) at 100 µM.
Compound Structure IC50 (µM)RmTIM
% Inhibition at
100 µM HmTIM
% Inhibition at
100 µM RbTIM
98
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3.4. Molecular Docking Simulation Analysis
Docking studies of compounds 50, 98, 161, and 14 contributed to elucidating how they interact
with residues from different regions of RmTIM. It was observed that compound 50 interacts with
amino acids located in alpha-helix 5 (Arg145, Lys148, and Glu140) (Figure 4A). Compound 98 interacts
with amino acids of alpha-helix 4 (Arg99, Lys103, Tyr67, and Asp105) (Figure 4B). Compound 161 was
located very near the active site (in a conserved zone) (data not shown) and Compound 14 interacts
with interface residues present in the loop 3 (Glu70, Gln71, Ser79, and Met82), and alpha-helix 1 (Gly16
and Ser17) (Figure 4C).
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3.5. In Vitro Inhibition of the BME26 Cell Line
The inhibitors 14, 50, 98, and 161, were assayed in the embryonic cell line BME26 using the MTT
assay (Figure 5). It was observed that cell viability at 100 µM was 20%, 42%, 40%, and 100% for
compounds 14, 50, 98, and 161, respectively. The IC50 values for the active compounds were 38 ±
4 µM (14), 71 ± 8 µM (50), and 67 ± 4 µM (98), respectively. Inhibitor 161 did not have any effect.
3.6. Effect of TIM Inhibitor 14 on the Physiology of the Tick
The effect of TIM inhibitor 14 on fully engorged females was analyzed by an adult immersion
test. When compared to vehicle compound, 14 was able to reduce the eclosion rate by 16% at different
concentrations (500 ppm and 2000 ppm) (Table 2). The effect on partially engorged females was
analyzed by injection of compound 14 into females treated during the artificial feeding procedure.
This resulted in 0% survival, when compared with a negative control. Consequently, no egg hatching
was observed (Table 3).
3.7. Effect of TIM Inhibitor in Oral Acute Toxicology in Mice
The LD50 value of the compound 14 for mammalian was 600 g/kg body weight. This is considered
a slight toxicity according to the World Health Organization guidelines.
Vet. Sci. 2018, 5, 74 10 of 19
Vet. Sci. 2018, 5, x FOR PEER REVIEW  9 of 19 
 
3.4. Molecular Docking Simulation Analysis 
Docking studies of compounds 50, 98, 161, and 14 contributed to elucidating how they interact 
with residues from different regions of RmTIM. It was observed that compound 50 interacts with 
amino acids located in alpha-helix 5 (Arg145, Lys148, and Glu140) (Figure 4A). Compound 98 
interacts with amino acids of alpha-helix 4 (Arg99, Lys103, Tyr67, and Asp105) (Figure 4B). 
Compound 161 was located very near the active site (in a conserved zone) (data not shown) and 
Compound 14 interacts with interface residues present in the loop 3 (Glu70, Gln71, Ser79, and Met82), 
and alpha-helix 1 (Gly16 and Ser17) (Figure 4C). 
   
Figure 4. Molecular docking studies for compounds 50, 98, and 14. Graphic representation of the 
interaction between each inhibitor with RmTIM. (A) Compound 50, amino acids from the active site 
are depicted in red. The zoom in the inset shows ligand–enzyme interactions at the binding site. (B) 
Compound 98, amino acids from the active site are depicted in red. The zoom in the inset shows 
ligand–enzyme interactions at the binding site. (C) Compound 14, amino acids from the active site 
are depicted in red. The zoom in the inset shows ligand–enzyme interactions at the binding site. 
3.5. In Vitro Inhibition of the BME26 Cell Line  
The inhibitors 14, 50, 98, and 161, were assayed in the embryonic cell line BME26 using the MTT 
assay (Figure 5). It was observed that cell viability at 100 μM was 20%, 42%, 40%, and 100% for 
compounds 14, 50, 98, and 161, respectively. The IC50 values for the active compounds were 38 ± 4 
μM (14), 71 ± 8 μM (50), and 67 ± 4 μM (98), respectively. Inhibitor 161 did not have any effect.  
 
Figure 5. In vitro activity of selected compounds on BME26 embryonic cells from Rhipicephalus 
microplus. (A–D) Confocal fluorescent microscopy of BME26 cells incubated for 24 h with different 
concentrations of compound 14. Following incubation, cells were stained with DAPI and phalloidin 
to observe the cell architecture (×100 magnification). (A) Control cells, (B) cells incubated with 25 μM 
Figure 5. In vitro activity of selected compounds on BME26 embryonic cells from
Rhipicephalus microplus. (A–D) Confocal fluorescent microscopy of BME26 cells incubated for 24 h with
different concentrations of compound 14. Following incubation, cells were stained with DAPI and
phalloidin to observe the cell architecture (×100 magnification). (A) Control cells, (B) cells incubated
with 25 µM of compound 14, (C) cells incubated with 50 µM of compound 14, (D) cells incubated with
100 µM of compound 14. (E) Dose–response effects for compounds 14, 98, and 50 in the MTT assay;
C is the control without treatment (0.1% (v/v) DMSO).
Table 2. Inhibitory effects of compound 14 on Rhipicephalus microplus fully engorged females by
immersion test. Larval weight F = 2.482. p value = 0.1639. Egg weight F = 5.254. p value = 0.0270,
survival expressed in percentage.
Group Total Oviposition Eggs Total Weight (mg) Larval Total Weight (mg) Eclosion Rate
PBS 14/15 133 ± 33 107 ± 47 79%
DMSO 13/15 110 ± 45 73 ± 45 67%
C14-2000 ppm 13/15 123 ± 35 63 ± 33 51% *
C14-500 ppm 15/15 113 ± 47 60 ± 39 51% *
Dose-dependent response of adults (AIT) to compound 14. The effects on the oviposition were calculated by the
ratio of ticks that completed oviposition/total, total eggs, and larval weight (mg). The eclosion rate was calculated
as described in Material and Methods. Standard deviation for each group was calculated. * represents statistical
significance. Statistical analyses were performed using one-way ANOVA followed by Tukey’s test.
Table 3. Inhibitory effects of compound 14 on Rhipicephalus microplus fully engorged females. Injection
of compound 14 into females treated during the artificial feeding procedure. Survival F = 126.9. p value
< 0.0001.
Treatment Oviposition/Total Total Egg Weight (mg) Total Larval Weight (mg) Eclosion Eclosion Rate
G1/PBS Buffer YES 10/13 30.32 ± 16.39 12.6 ± 9.88 YES 43%
G2/DMSO YES 3/13 48.67 ± 23.54 23.33 ± 16.92 YES 47%
G3/C14 NO 0/13 - - NO -
Partially engorged female ticks were separated into homogeneous groups (G1, G2, and G3) and received a different
treatment. The numbers are represented by the ratio of ticks that realized oviposition/total of ticks per group,
and females that did not lay eggs were considered dead. Egg samples of each group were collected, subsequently
weighed, and were represented by mass (milligram). ± represents the standard deviation from each group.
- represents that oviposition did not occur. Statistical analyses were performed using one-way ANOVA followed by
Tukey’s test.
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4. Discussion
An important source for the discovery of new drugs is the in vitro screening of chemical libraries
using a validated target. In vitro screening has been very useful in many areas of health, such as cancer,
cardiovascular and kidney diseases, infection control of many pathogens (viruses, parasites, bacteria,
and fungus) [45–48]. One of the criteria for the election of a molecular target is selectivity. A selected
target, to fight a pathogen, needs to be different to the host biomolecules. The deduced amino acid
sequence of RmTIM had high similarity with other sequences from TIMs of other ticks and Bos taurus.
Interestingly, different numbers of cysteine residues were observed in the sequences. There were five
cysteine residues that are present in almost all tick TIMs, but are not present in B. taurus (the natural
host of R. microplus) (Figure S1 in supporting information). A phylogenetic analysis of different tick
TIMs was constructed using the amino acid sequences studied (Figure 1). The phylogenetic tree
revealed two clades: one clade included R. microplus and Amblyomma spp. TIMs, and the other was
formed by Ixodes spp. As expected, B. taurus TIM segregated into a well-separated clade. The major
differences among these sequences are in the dimer interface [49], which gives the possibility to find a
selective inhibitor that interacts with the dimer interface [29,50]. TIM from B. taurus is not yet available
for use in inhibition assays, but the structurally very similar TIM from rabbit is (RbTIM). We used
RbTIM for the selectivity studies [51,52].
In this work, an initial screening was performed using 227 compounds from an in-house
chemo-library, selected according to previous reports of their activity against other parasites [15,53–55].
The choice was based on chemical structures that included different families of compounds, which were
benzofuroxans, benzimidazoles, thiadiazines, hydrazide derivatives, thiazolylidene hydrazines,
flavonoids, furoxans, phenazines, thiadiazoles, indazoles, quinoxalines, and triazines, among others
(Figure 2A). Until the present date, no molecule with any of these chemical structures, or another
structure, has been reported to be a specific inhibitor of RmTIM.
The inhibitory capacity of these 227 compounds was tested in vitro against RmTIM using an
initial concentration of 100 µM. Under these conditions, 50% inhibition of RmTIM activity was defined
as an arbitrary cut-off point in order to define the molecules that were to be considered for more
detailed studies. Based on this criterion (50% inhibition of RmTIM activity at 100 µM, Table S1) only
some compounds belonging to some families were active, and the thiadiazines and furoxans showed
the highest scores (±15% of these molecules were active). Among the hydrazide derivatives, 9% of the
molecules were active, and within the other families, only 3% of the evaluated compounds displayed
RmTIM inhibitory activity. Based on this criterion, sixteen compounds from all the chemotypes
(7% of the tested molecules, Figure 3) were selected for the study of their inhibitory capacity at
different concentrations, in order to determine the IC50 values. In addition, the selectivity of the four
compounds with highest inhibition capacity compound 98 (hydrazide family), 50 (thiadiazine family),
161 (thiadiazole family), and 14 (benzofuroxan family)) (Table 1) against RmTIM were assayed by
comparing their performance against HsTIM and RbTIM, which has a sequence identity of 98% with
B. taurus TIM.
Interestingly, the inhibitory activity of the compounds against RmTIM shows significantly lower
values when compared with the IC50 previously obtained for Trypanosoma cruzi TIM (TcTIM), indicating
higher potency as inhibitors. Compound 161 was the most active against RmTIM, although it also
displayed a slight inhibitory activity against HsTIM at 100 µM (Table 1). Also, this compound had
an IC50 of 4 µM for TcTIM vs the 25 µM in RmTIM. Compounds 98, 50, and 14 showed medium
inhibitory activity (around 50 µM for the IC50). On the other hand, they did not affect the mammalian
TIMs, showing a desirable selectivity profile. Compounds 161 and 50 have more complex synthetic
procedures, while compounds 98 and 14 are simpler to prepare. In addition, these last two compounds
support structural modifications, which are important for future improvement in molecular synthesis
for obtaining a better biological activity. In particular, a wide spectrum of structural modifications was
included in the initial screening for the thiadiazine family, but only the arrangement of compound 50
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was successful, suggesting that a future modification to obtain a more active molecule with easy and
low-cost synthetic procedures cannot be possible.
It is important to highlight that these four molecules are the first inhibitors reported, until
now, for RmTIM. Usually, it is expected the inhibition range may be lower than 10 µM, however,
the search for species-specific drugs could vary according to various parameters, including the target,
the disease, model organisms, and pharmaceutical formulation [56–58]. Nonetheless, there are few
manuscripts on drug design against others arthropods to compare the potency of the candidate
compounds identified [59–62]. It is significant to observe that these four molecules are selective
molecules, since they have a negligible effect on mammalian TIMs, even when used at a 4-fold higher
dose than their IC50 for RmTIM. Furthermore, these are lead compounds which can be improved with
further chemical modifications [63,64].
Energy metabolism is essential during embryogenesis of the cattle tick. Marker enzymes of
metabolic pathways, such as hexokinase and pyruvate kinase, show high levels, before formation of
the cellular blastoderm [65]. Enzymes of the gluconeogenesis pathway have more activity after this
point, and are responsible for glycogen accumulation that can be used as an energy source, until the
eclosion of the embryos [65]. TIM is an enzyme involved in both processes that could act in different
metabolic situations [13]. Therefore, these molecules represent promising lead compounds in the
search of effective drugs against these parasites, and could potentially be developed as novel acaricides.
Also, these structures are very different to the commercial acaricides, and this characteristic can be
useful to bypass the resistance observed in different field populations of ticks [5,66].
In order to explore the mode of binding of compounds 50, 98, and 14 to RmTIM, molecular
docking experiments were performed, mapping the entire protein surface of the dimer. Compound 50
binds on the surface of the enzyme, establishing a weak hydrogen bond (3.2 Å) between one oxygen
atom of the nitro moiety of the ligand and the Nα nitrogen of Lys148, and also has pi–cation and
pi–anion interactions with Arg145 and Glu140, respectively (Figure 4A). The binding mode of this
compound could explain its lower activity since, being weakly bound to the surface of the protein and
taking into account the high flexibility of this kind of enzyme [67,68], it could be prone to expulsion
into the solvent by the normal dynamics of RmTIM. Compound 98 also binds superficially to RmTIM,
forming a hydrogen bond of 3.0 Å with Tyr67, and makes contacts with the amino acids that form
alpha-helix 4, such as Arg99, Lys103, and Asp105 (Figure 4B).
Compound 14 binds to the dimer interface interacting with residues on loop 3 (Glu70, Gln71,
Ser79, and Met82) and on alpha-helix 1 (Gly16 and Ser17) (Figure 4C). This compound establishes two
strong hydrogen bonds with Gln71 from chain A and Gly16 from chain B (2.8 Å and 2.9 Å, respectively),
a fact that would contribute to its stabilization within the binding site. The location of this compound
near loop 3 is interesting, considering its inhibitory potency, since residues in this loop are involved in
hydrogen bond interactions with loop 1 of the other subunit, helping to maintain the integrity of the
dimer. According to these docking results, this compound could be acting through the perturbation of
the interface region, leading to the disruption of the dimer, as has been already reported for other TIM
inhibitors [14,16,69]. Moreover, this region of the protein is less conserved among TIMs, a fact that
would explain the high selectivity of compound 14 against RmTIM.
To improve and complement the characterization, the selected inhibitors, 14, 50, 98, and 161,
were assayed with the R. microplus embryonic cell line BME26 using the MTT assay (Figures 5 and S2).
Compound 161 showed no activity at a concentration of 100 µM in the assayed conditions. Although
this compound was the best inhibitor against RmTIM and TcTIM in the enzyme test, the incapacity to
inhibit the TIM activity in BME26 cells can be explained since, in previous work, it was found that
compound 161 cannot penetrate biological membranes [53]. The IC50 for benzofuroxan 14 was 30 ±
4 µM (tenfold less active than ivermectin (3 µM)) a widely used acaricide [8,42]. Besides the lower
activity of compound 14, compared to ivermectin, this compound is structurally simple and has a
lower cost of production. On the other hand, thiadiazine 50 and hydrazide 98 were less active in
BME26 cells, with IC50 values near 50 µM.
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The detoxification of acaricides occurs due to families of genes involving different enzymes,
such as the cytochrome P450 superfamily [70,71]. Methylglyoxal is a glycolytic intermediate,
which may reach high levels when TIM levels decrease in the cell. It acts as a highly reactive
electrophile that glycates and crosslinks proteins or DNA through the formation of advanced glycation
end products [72,73].
The viability of BME26 cells was reduced at high concentrations of compound 14 (Figure 5).
This molecule has been shown to have low toxicity for human cells [74] and has no toxic effects on
murine cells at a concentration of 100 µM [75]. Besides that, toxicological data are available [76–78].
Moreover, this molecule was reported to have agricultural applications as a herbicide and in
phytopathogen control [79,80]. In this context, compound 14 is an interesting prototype for future
chemical modifications to enhance its acaricidal activity [81].
Finally, we performed a proof of concept experiment of the acaricidal potential of compound 14
using the adult immersion test (Table 2). To evaluate a topical application of compound 14, we test
the concentrations of 500 and 2000 ppm, and the results showed a reduction of 16% in the eclosion
rate. Similar results were reported with coumaphos, a commercial acaricide, at a concentration of
500 ppm [82]. These results are not promising because of the solubility problem of the compound.
Typical immersion tests use aqueous solutions, then this compound was low soluble in this test
conditions. If the compound is a solid suspension in the immersion test, there will not be absorption
into the animals, and then there are no toxic effects. To resolve this kind of problem, a structural
modification of the compound is needed to improve the solubility, to be applicable in a bath on the
fields as an agrochemical. Also, could be performed a better formulation for the baths like more
lipophilic solution, but this is not useful in the immersion test.
Besides that, partially engorged ticks were injected with 2 nmol/tick of this compound, and fed
in an artificial feeding assay [41]. The biological effect was observed by an induced mortality of 100%
(Table 3). The acute oral LD50 value of the compound 14 was 600 mg/kg body weight, while other
well-known acaricides had lower values in mice, such as fipronil (91 mg/kg) [83] and coumaphos
(28 mg/kg) [84]. Some difficulties were found with DMSO that was used as a vehicle; the solubility
was improved but there is some intrinsic toxicity because of the DMSO, but the effect from the
administration of the compound 14 was clearly observed. The mortality was improved compared to
DMSO treatment. This result suggests that compound 14 could be a promising acaricide and also a
novel scaffold for new acaricide development, with a novel mechanism of action.
5. Conclusions
In conclusion, in this study, we screened 227 compounds, from which four were found
to be particularly active and specific inhibitors of RmTIM. Among these, compound 14
(7-nitrobenzo[c][1,2,5]oxadiazole 1-oxide) is a molecule that can be obtained by a simple synthetic
procedure, and can be produced on a large scale (Figure 6). Moreover, it shows inhibitory activity
against RmTIM, together with an adequate specificity. In addition, this molecule, the first RmTIM
inhibitor reported, showed acaricidal activity in biological assays. It is important to highlight that the
resistance to commercial acaricides has increased over the years. A molecule with a different structure
and mechanism of action, such as compound 14, is important to bypass the resistance present in field
tick populations. Also, this molecule has a low toxicity that is within the limits of the Food and Drug
Administration (FDA) for a safe drug. The four molecules identified here are hits for the development
of new acaricidal drugs.
Vet. Sci. 2018, 5, 74 14 of 19
Vet. Sci. 2018, 5, x FOR PEER REVIEW  14 of 20 
 
 
Figure 6. Drug Candidate Profile. An abstract of the pharmacological information compiled in this 
work for the identified hit compounds 14, 50, and 98. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Multiple 
alignment of the amino acid sequence among TIM from different ticks and B. Taurus, Figure S2: In vitro activity 
in BME26 embryonic cell from R. microplus, Table S1: Chemical structure of compounds used in primary 
screening. 
Author Contributions: Methodology: L.S., H.G., E.A., M.C., M.F.A., R.N.d.F., B.A.-L., N.C.; Formal Analysis: 
L.S., H.G., E.A., M.C., M.F.A., R.N.d.F., B.A.-L., N.C.; Investigation: L.S., H.G., E.A., M.C., M.F.A., R.N.d.F., B.A.-
L., N.C.; Data Curation: L.S., I.d.S.V.J., J.M., G.Á.; Writing-Original Draft Preparation: L.S., J.M., G.Á.; Writing-
Review & Editing: I.d.S.V.J., R.P.-M., H.C., M.G.; Supervision: J.M., G.Á.; Project Administration: A.M., J.M., 
G.Á.; Funding Acquisition: R.P.-M., A.M., J.M., G.Á. 
Funding: This research was supported by grants from Conselho Nacional de Pesquisa e Desenvolvimento 
Científico (CNPq) and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)-
Brasil, Direccion Investigacion, Ciencia y Tecnologia (DICyT), Ministerio de Educación y Cultura (MEC), Uruguay 
(G.Á and J.M.). CONACyT-México No. 254694 (to R.P.-M.), The APC was funded by PEDECIBA-Programa de 
Desarrollo de las Ciencias Básicas, Universidad de la República-Ministerio de Educación y Cultura 
Acknowledgments: We are also grateful to Alejandro Flores Rodríguez of the Instituto de Fisiología Celular, 
Universidad Nacional Autónoma de México for his excellent technical assistance. We dedicate this paper to the 
memory of a two great women scientists Mercedes González and Alicia Merlino. Two great fighters in life and 
in science, rest in peace. 
Conflicts of Interest: The authors declare no conflict of interest. 
Figure 6. Drug Candidate Profile. n abstract of the phar acological infor ation co piled in this
ork for the identified hit compounds 14, 50, and 98.
Supplementary Materials: The following are available online at http://www.mdpi.com/2306-7381/5/3/74/s1,
Figure S1: Multiple alignment of the amino acid sequence among TIM from different ticks and B. Taurus, Figure S2:
I vitro activity in BME26 embryonic cell from R. microplus, Table S1: Chemical structure of compounds used in
primary screening.
Author Contributions: Methodology: L.S., H.G., E.A., M.C., M.F.A., R.N.d.F., B.A.-L., N.C.; Formal Analysis: L.S.,
H.G., E.A., M.C., M.F.A., R.N.d.F., B.A.-L., N.C.; Investigation: L.S., H.G., E.A., M.C., M.F.A., R.N.d.F., B.A.-L.,
N.C.; Data Curation: L.S., I.d.S.V.J., J.M., G.Á.; Writing-Original Draft Preparation: L.S., J.M., G.Á.; Writing-Review
& Editing: I.d.S.V.J., R.P.-M., H.C., M.G.; Supervision: J.M., G.Á.; Project Administration: A.M., J.M., G.Á.; Funding
Acquisition: R.P.-M., A.M., J.M., G.Á.
Funding: This research was supported by grants from Conselho Nacional de Pesquisa e Desenvolvimento
Científico (CNPq) and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
(FAPERJ)-Brasil, Direccion Investigacion, Ciencia y Tecnologia (DICyT), Ministerio de E uc ción y Cultura
(MEC), Uruguay (G.Á and J.M.). CONACyT-México No. 254694 (to R.P.-M.), The APC was funded by
PEDECIBA-Programa de Desarrollo de las Ciencias Básicas, Universidad de la República-Ministerio de Educación
y Cultura.
Acknowledgments: We are also grateful to Alejandro Flores Rodríguez of the Instituto de Fisiología Celular,
Universidad Nacional Autónoma de México for his excellent technical assistance. We dedicate this paper to the
memory of a two gre t women scientists Mercedes González and Ali ia Merlino. Two great fighters in lif and in
sci nce, rest in peace.
Vet. Sci. 2018, 5, 74 15 of 19
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Karbanowicz, T.P.; Nouwens, A.; Tabor, A.E.; Rodriguez-Valle, M. Comparison of protein gut samples from
Rhipicephalus spp. using a crude and an innovative preparation method for proteome analysis. Vet. Sci. 2018,
5, 30. [CrossRef] [PubMed]
2. Jonsson, N.N. The productivity effects of cattle tick (Boophilus microplus) infestation on cattle, with particular
reference to Bos indicus cattle and their crosses. Vet. Parasitol. 2006, 137, 1–10. [CrossRef] [PubMed]
3. Hajdušek, O.; Síma, R.; Ayllón, N.; Jalovecká, M.; Perner, J.; de la Fuente, J.; Kopácˇek, P. Interaction of the tick
immune system with transmitted pathogens. Front. Cell. Infect. Microbiol. 2013, 3, 26. [CrossRef] [PubMed]
4. Graf, J.F.; Gogolewski, R.; Leach-Bing, N.; Sabatini, G.A.; Molento, M.B.; Bordin, E.L.; Arantes, G.J. Tick
control: An industry point of view. Parasitology 2004, 129 (Suppl. S1), S427–S442. [CrossRef] [PubMed]
5. Klafke, G.; Webster, A.; Dall Agnol, B.; Pradel, E.; Silva, J.; de La Canal, L.H.; Becker, M.; Osório, M.F.;
Mansson, M.; Barreto, R.; et al. Multiple resistance to acaricides in field populations of Rhipicephalus microplus
from Rio Grande do Sul state, Southern Brazil. Ticks Tick. Borne Dis. 2017, 8, 73–80. [CrossRef] [PubMed]
6. Abbas, R.Z.; Zaman, M.A.; Colwell, D.D.; Gilleard, J.; Iqbal, Z. Acaricide resistance in cattle ticks and
approaches to its management: The state of play. Vet. Parasitol. 2014, 203, 6–20. [CrossRef] [PubMed]
7. Li, A.Y.; Davey, R.B.; Miller, R.J.; George, J.E. Detection and Characterization of Amitraz Resistance in the
Southern Cattle Tick, Boophilus microplus (Acari: Ixodidae). J. Med. Entomol. 2004, 41, 193–200. [CrossRef]
[PubMed]
8. Pohl, P.C.; Carvalho, D.D.; Daffre, S.; Vaz, S.; Masuda, A. In vitro establishment of ivermectin-resistant
Rhipicephalus microplus cell line and the contribution of ABC transporters on the resistance mechanism.
Vet. Parasitol. 2014, 204, 316–322. [CrossRef] [PubMed]
9. Nandi, A.; Sagar, S.V.; Chigure, G.; Fular, A.; Sharma, A.K.; Nagar, G.; Kumar, S.; Saravanan, B.C.; Ghosh, S.
Determination and validation of discriminating concentration of ivermectin against Rhipicephalus microplus.
Vet. Parasitol. 2018, 250, 30–34. [CrossRef] [PubMed]
10. Castro-Janer, E.; Martins, J.R.; Mendes, M.C.; Namindome, A.; Klafke, G.M.; Schumaker, T.T. Diagnoses
of fipronil resistance in Brazilian cattle ticks (Rhipicephalus (Boophilus) microplus) using in vitro larval
bioassays. Vet. Parasitol. 2010, 173, 300–306. [CrossRef] [PubMed]
11. Parizi, L.F.; Pohl, P.C.; Masuda, A.; Junior, V.; da Silva, I. New approaches toward anti-Rhipicephalus
(Boophilus) microplus tick vaccine. Rev. Bras. Parasitol. Vet. 2009, 18, 1–7. [CrossRef] [PubMed]
12. Mulenga, A.; Kim, T.K.; Ibelli, A.M.G. Deorphanization and target validation of cross-tick species conserved
novel Amblyomma americanum tick saliva protein. Int. J. Parasitol. 2013, 43, 439–451. [CrossRef] [PubMed]
13. Saramago, L.; Franceschi, M.; Logullo, C.; Masuda, A.; Vaz Ida, S.; Farias, S.E.; Moraes, J. Inhibition of
enzyme activity of Rhipicephalus (Boophilus) microplus triosephosphate isomerase and BME26 cell growth
by monoclonal antibodies. Int. J. Mol. Sci. 2012, 13, 13118–13133. [CrossRef] [PubMed]
14. Maithal, K.; Ravindra, G.; Balaram, H.; Balaram, P. Inhibition of Plasmodium falciparum triose-phosphate
isomerase by chemical modification of an interface cysteine: Electrospray ionization mass spectrometric
analysis of differential cysteine reactivities. J. Biol. Chem. 2002, 277, 25106–25114. [CrossRef] [PubMed]
15. Aguilera, E.; Varela, J.; Birriel, E.; Serna, E.; Torres, S.; Yaluff, G.; DeBilbao, N.V.; Aguirre-López, B.;
Cabrera, N.; DíazMazariegos, S.; et al. Potent and Selective Inhibitors of Trypanosoma cruzi Triosephosphate
Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget
Activity. ChemMedChem 2016, 11, 1328–1338. [CrossRef] [PubMed]
16. Olivares-Illana, V.; Rodríguez-Romero, A.; Becker, I.; Berzunza, M.; García, J.; Pérez-Montfort, R.; Cabrera, N.;
López-Calahorra, F.; de Gómez-Puyou, M.T.; Gómez-Puyou, A. Perturbation of the Dimer Interface of
Triosephosphate Isomerase and its Effect on Trypanosoma cruzi. PLoS Negl. Trop. Dis. 2007, 1, e1. [CrossRef]
[PubMed]
17. Moraes, J.; Arreola, R.; Cabrera, N.; Saramago, L.; Freitas, D.; Masuda, A.; da Silva Vaz, I., Jr.;
Tuena de Gomez-Puyou, M.; Perez-Montfort, R.; Gomez-Puyou, A.; et al. Structural and biochemical
characterization of a recombinant triosephosphate isomerase from Rhipicephalus (Boophilus) microplus.
Insect Biochem. Mol. Biol. 2011, 41, 400–409. [CrossRef] [PubMed]
Vet. Sci. 2018, 5, 74 16 of 19
18. Téllez-Valencia, A.; Olivares-Illana, V.; Hernández-Santoyo, A.; Pérez-Montfort, R.; Costas, M.;
Rodríguez-Romero, A.; López-Calahorra, F.; Tuena De Gómez-Puyou, M.; Gómez-Puyou, A. Inactivation of
Triosephosphate Isomerase from Trypanosoma cruzi by an Agent that Perturbs its Dimer Interface. J. Mol. Biol.
2004, 341, 1355–1365. [CrossRef] [PubMed]
19. Reck, J.; Klafke, G.M.; Webster, A.; Agnol, B.D.; Scheffer, R.; Souza, U.A.; Corassini, V.B.; Vargas, R.; Silveira, J.;
Ricardo, J.; et al. First report of fluazuron resistance in Rhipicephalus microplus: A field tick population resistant
to six classes of acaricides. Vet. Parasitol. 2014, 201, 128–136. [CrossRef] [PubMed]
20. Eiden, A.L.; Kaufman, P.E.; Oi, F.M.; Dark, M.J.; Bloomquist, J.R.; Miller, R.J. Determination of metabolic
resistance mechanisms in pyrethroid-resistant and fipronil-tolerant brown dog ticks. Med. Vet. Entomol. 2017,
31, 243–251. [CrossRef] [PubMed]
21. Pavela, R.; Canale, A.; Mehlhorn, H.; Benelli, G. Application of ethnobotanical repellents and acaricides in
prevention, control and management of livestock ticks: A review. Res. Vet. Sci. 2016, 109, 1–9. [CrossRef]
[PubMed]
22. Harrison, I.R.; Kozlik, A.; Mccarthy, J.F.; Palmer, B.H.; Wakerley, S.B.; Watkins, T.I.; Weighton, D.M.
1,3,5-Triazapenta-1,4-dienes: Chemical Aspects of a New Group of Pesticides. Pestic. Sci. 1973, 4, 901–910.
[CrossRef]
23. Bull, M.; Swindale, S.; Doverend, D.; Hess, E. Suppression of Boophilus microplus populations with fluazuron:
An acarine growth regulator. Aust. Vet. J. 1996, 74, 468–470. [CrossRef] [PubMed]
24. Rodríguez-Vivas, R.I.; Pérez-Cogollo, L.C.; Rosado-Aguilar, J.A.; Ojeda-Chi, M.M.; Trinidad-Martinez, I.;
Miller, R.J.; Li, A.Y.; Pérez de León, A.; Guerrero, F.; Klafke, G. Rhipicephalus (Boophilus) microplus resistant
to acaricides and ivermectin in cattle farms of Mexico. Rev. Bras. Parasitol. Vet. 2014, 23, 113–122. [CrossRef]
[PubMed]
25. Silva, W.C.; Martins, J.R.D.S.; Cesio, M.V.; Azevedo, J.L.; Heinzen, H.; de Barros, N.M. Acaricidal activity of
Palicourea marcgravii, a species from the Amazon forest, on cattle tick Rhipicephalus (Boophilus) microplus.
Vet. Parasitol. 2011, 179, 189–194. [CrossRef] [PubMed]
26. Ghosh, S.; Tiwari, S.S.; Srivastava, S.; Sharma, A.K.; Kumar, S.; Ray, D.D.; Rawat, A.K. Acaricidal properties of
Ricinus communis leaf extracts against organophosphate and pyrethroids resistant Rhipicephalus (Boophilus)
microplus. Vet. Parasitol. 2013, 192, 259–267. [CrossRef] [PubMed]
27. De Oliveira Souza Senra, T.; Zeringóta, V.; de Oliveira Monteiro, C.M.; Calmon, F.; Maturano, R.;
Gomes, G.A.; Faza, A.; de Carvalho, M.G.; Daemon, E. Assessment of the acaricidal activity of carvacrol,
(E)-cinnamaldehyde, trans-anethole, and linalool on larvae of Rhipicephalus microplus and Dermacentor
nitens (Acari: Ixodidae). Parasitol. Res. 2013, 112, 1461–1466. [CrossRef] [PubMed]
28. Yu, X.; Liu, Y.; Li, Y.; Wang, Q. Design, Synthesis, Acaricidal/Insecticidal Activity, and Structure-Activity
Relationship Studies of Novel Oxazolines Containing Sulfone/Sulfoxide Groups Based on the Sulfonylurea
Receptor Protein-Binding Site. J. Agric. Food Chem. 2016, 64, 3034–3040. [CrossRef] [PubMed]
29. Alvarez, G.; Aguirre-López, B.; Varela, J.; Cabrera, M.; Merlino, A.; López, G.V.; Lavaggi, M.L.; Porcal, W.;
Di Maio, R.; González, M.; et al. Massive screening yields novel and selective Trypanosoma cruzi
triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity. Eur. J.
Med. Chem. 2010, 45, 5767–5772. [CrossRef] [PubMed]
30. Cerecetto, H.; González, M. Anti-T. cruzi agents: Our experience in the evaluation of more than five hundred
compounds. Mini Rev. Med. Chem. 2008, 8, 1355–1383. [CrossRef] [PubMed]
31. Reck, J.; Berger, M.; Terra, R.M.S.; Marks, F.S.; da Silva Vaz, I.; Guimarães, J.A.; Termignoni, C. Systemic
alterations of bovine hemostasis due to Rhipicephalus (Boophilus) microplus infestation. Res. Vet. Sci. 2009,
86, 56–62. [CrossRef] [PubMed]
32. Hall, T.A. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows
95/98/NT. Nucleic Acids Symp. Ser. 1999, 41, 95–98.
33. Nicholas, K.B.; Nicholas, H.B.J.; Deerfield, D.W.I. Analysis and Visualization of Genetic Variation.
EMBNet News 1997, 4, 14.
34. Tamura, K.; Stecher, G.; Peterson, D.; Filipski, A.; Kumar, S. MEGA6: Molecular evolutionary genetics
analysis version 6.0. Mol. Biol. Evol. 2013, 30, 2725–2729. [CrossRef] [PubMed]
Vet. Sci. 2018, 5, 74 17 of 19
35. Aguirre, B.; Costas, M.; Cabrera, N.; Mendoza-Hernandez, G.; Helseth, D.L., Jr.; Fernandez, P.;
de Gomez-Puyou, M.T.; Perez-Montfort, R.; Torres-Larios, A.; Gomez Puyou, A. A ribosomal
misincorporation of Lys for Arg in human triosephosphate isomerase expressed in Escherichia coli gives rise
to two protein populations. PLoS ONE 2011, 6, e21035. [CrossRef] [PubMed]
36. Pace, C.N.; Vajdos, F.; Fee, L.; Grimsley, G.; Gray, T. How to measure and predict the molar absorption
coefficient of a protein. Protein Sci. 1995, 4, 2411–2423. [CrossRef] [PubMed]
37. Da Silva, R.M.; Noce, B.D.; Waltero, C.F.; Costa, E.P.; de Abreu, L.A.; Githaka, N.W.; Moraes, J.; Gomes, H.F.;
Konnai, S.; Vaz Ida, S., Jr.; et al. Non-classical gluconeogenesis-dependent glucose metabolism in
Rhipicephalus microplus embryonic cell line BME26. Int. J. Mol. Sci. 2015, 16, 1821–1839. [CrossRef]
[PubMed]
38. Esteves, E.; Lara, F.A.; Lorenzini, D.M.; Costa, G.H.N.; Fukuzawa, A.H.; Pressinotti, L.N.; Silva, J.R.M.C.;
Ferro, J.A.; Kurtti, T.J.; Munderloh, U.G.; et al. Cellular and molecular characterization of an embryonic cell
line (BME26) from the tick Rhipicephalus (Boophilus) microplus. Insect Biochem. Mol. Biol. 2008, 38, 568–580.
[CrossRef] [PubMed]
39. Oba, M.S.P.; de Campos Pereira, M.; de Almeida, M.A.C. Ensaios in vitro pelos critérios de oba drummond
de chlorpyrifos sobre linhagem supostamente resistente de Boophilus microplus. Rev. Fac. Med. Vet. Zootec.
Univ. São Paulo 1976, 13, 409–420. [CrossRef]
40. Fabres, A.; De Andrade, C.P.; Guizzo, M.; Sorgine, M.H.F.; Paiva-Silva, G.D.O.; Masuda, A.; Vaz Ida, S., Jr.;
Logullo, C. Effect of GSK-3 activity, enzymatic inhibition and gene silencing by RNAi on tick oviposition
and egg hatching. Parasitology 2010, 137, 1537–1546. [CrossRef] [PubMed]
41. Gonsioroski, A.V.; Bezerra, I.A.; Utiumi, K.U.; Driemeier, D.; Farias, S.E.; da Silva Vaz, I.; Masuda, A. Anti-tick
monoclonal antibody applied by artificial capillary feeding in Rhipicephalus (Boophilus) microplus females.
Exp. Parasitol. 2012, 130, 359–363. [CrossRef] [PubMed]
42. Pohl, P.C.; Klafke, G.M.; Carvalho, D.D.; Martins, J.R.; Daffre, S.; da Silva Vaz, I., Jr.; Masuda, A. ABC
transporter efflux pumps: A defense mechanism against ivermectin in Rhipicephalus (Boophilus) microplus.
Int. J. Parasitol. 2011, 41, 1323–1333. [CrossRef] [PubMed]
43. OECD. OECD Guidelines for the Testing of Chemicals, Section 4, Test No. 425: Acute Oral
Toxicity—Up-and-Down Procedure. Guidel. Test. Chem. 2001, 26. [CrossRef]
44. Álvarez, G.; Varela, J.; Cruces, E.; Fernández, M.; Gabay, M.; Leal, S.M.; Escobar, P.; Sanabria, L.; Serna, E.;
Torres, S.; et al. Identification of a new amide-containing thiazole as a drug candidate for treatment of chagas’
disease. Antimicrob. Agents Chemother. 2015, 59, 1398–1404. [CrossRef] [PubMed]
45. Deng, W.; Zhu, N.; Mo, J. In vitro bioassay methods for laboratory screening of novel mosquito repellents.
Entomol. Sci. 2014, 17, 365–370. [CrossRef]
46. Wimmersberger, D.; Tritten, L.; Keiser, J. Development of an in vitro drug sensitivity assay for Trichuris muris
first-stage larvae. Parasit. Vectors 2013, 6, 42. [CrossRef] [PubMed]
47. Picazo, E.; Giordanetto, F. Small molecule inhibitors of ebola virus infection. Drug Discov. Today 2014, 20,
277–286. [CrossRef] [PubMed]
48. Quincoces Suarez, J.A.; Rando, D.G.; Santos, R.P.; Gonalves, C.P.; Ferreira, E.; De Carvalho, J.E.; Kohn, L.;
Maria, D.A.; Faião-Flores, F.; Michalik, D.; et al. New antitumoral agents I: In vitro anticancer activity and
in vivo acute toxicity of synthetic 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadien-3-one and derivatives.
Bioorg. Med. Chem. 2010, 18, 6275–6281. [CrossRef] [PubMed]
49. Dynamics, I.; Kurkcuoglu, Z.; Findik, D.; Akten, E.D.; Doruker, P. How an Inhibitor Bound to Subunit
Interface Alters Triosephosphate. Biophys. J. 2015, 109, 1169–1178.
50. Olivares-Illana, V.; Perez-Montfort, R.; Lopez-Calahorra, F.; Costas, M.; Rodriguez-Romero, A.;
Tuena de Gomez-Puyou, M.; Gomez Puyou, A. Structural differences in triosephosphate isomerase from
different species and discovery of a multitrypanosomatid inhibitor. Biochemistry 2006, 45, 2556–2560.
[CrossRef] [PubMed]
51. Fonvielle, M.; Mariano, S.; Therisod, M. New inhibitors of rabbit muscle triose-phosphate isomerase.
Bioorg. Med. Chem. Lett. 2005, 15, 2906–2909. [CrossRef] [PubMed]
52. Gomez-Puyou, A.; Saavedra-Lira, E.; Becker, I.; Zubillaga, R.A.; Rojo-Dominguez, A.; Perez-Montfort, R.
Using evolutionary changes to achieve species-specific inhibition of enzyme action—Studies with
triosephosphate isomerase. Chem. Biol. 1995, 2, 847–855. [CrossRef]
Vet. Sci. 2018, 5, 74 18 of 19
53. Alvarez, G.; Aguirre-López, B.; Cabrera, N.; Marins, E.B.; Tinoco, L.; Batthyány, C.I.; de Gómez-Puyou, M.T.;
Puyou, A.G.; Pérez-Montfort, R.; Cerecetto, H.; et al. 1,2,4-thiadiazol-5(4H)-ones: A new class of selective
inhibitors of Trypanosoma cruzi triosephosphate isomerase. Study of the mechanism of inhibition. J. Enzyme
Inhib. Med. Chem. 2013, 28, 981–989. [CrossRef] [PubMed]
54. Alvarez, G.; Martinez, J.; Aguirre-Lopez, B.; Cabrera, N.; Perez-Diaz, L.; de Gomez-Puyou, M.T.;
Gomez-Puyou, A.; Perez-Montfort, R.; Garat, B.; Merlino, A.; et al. New chemotypes as Trypanosoma cruzi
triosephosphate isomerase inhibitors. A deeper insight into the mechanism of inhibition. J. Enzym. Inhib
Med. Chem. 2014, 29, 198–204. [CrossRef] [PubMed]
55. Álvarez, G.; Martínez, J.; Varela, J.; Birriel, E.; Cruces, E.; Gabay, M.; Leal, S.M.; Escobar, P.; Aguirre-López, B.;
Cabrera, N.; et al. Development of bis-thiazoles as inhibitors of triosephosphate isomerase from
Trypanosoma cruzi. Identification of new non-mutagenic agents that are active in vivo. Eur. J. Med. Chem.
2015, 100, 246–256. [CrossRef] [PubMed]
56. Renslo, A.R.; McKerrow, J.H. Drug discovery and development for neglected parasitic diseases.
Nat. Chem. Biol. 2006, 2, 701–710. [CrossRef] [PubMed]
57. Zheng, C.; Guo, Z.; Huang, C.; Wu, Z.; Li, Y.; Chen, X.; Fu, Y.; Ru, J.; Ali Shar, P.; Wang, Y.; et al. Large-scale
Direct Targeting for Drug Repositioning and Discovery. Sci. Rep. 2015, 5, 11970. [CrossRef] [PubMed]
58. Cavalli, A.; Bolognesi, M.L. Neglected tropical diseases: Multi-target-directed ligands in the search for
novel lead candidates against Trypanosoma and Leishmania. J. Med. Chem. 2009, 52, 7339–7359. [CrossRef]
[PubMed]
59. Luo, J.; Lai, T.; Guo, T.; Chen, F.; Zhang, L.; Ding, W.; Zhang, Y. Synthesis and acaricidal activities of scopoletin
phenolic ether derivatives: Qsar, molecular docking study and in silico Adme predictions. Molecules 2018, 23.
[CrossRef] [PubMed]
60. Davey, R.B.; Pound, J.M.; Miller, J.A.; Klavons, J.A. Therapeutic and persistent efficacy of a long-acting
(LA) formulation of ivermectin against Rhipicephalus (Boophilus) microplus (Acari: Ixodidae) and sera
concentration through time in treated cattle. Vet. Parasitol. 2010, 169, 149–156. [CrossRef] [PubMed]
61. Chen, D.; Tian, Y.; Xu, M.; Wang, X.; Li, D.; Miao, F. Design, Bioactivity and structure- activity of
3-Arylpropionate Derivatives as Potential High- Efficient Acaricides against Psoroptes Cuniculi. Sci. Rep.
2018, 8, 1797. [CrossRef] [PubMed]
62. Shang, X.F.; Liu, Y.Q.; Guo, X.; Miao, X.L.; Chen, C.; Zhang, J.X.; Xu, X.S.; Yang, G.Z.; Yang, C.J.; Li, J.C.; et al.
Application of Sustainable Natural Resources in Agriculture: Acaricidal and Enzyme Inhibitory Activities
of Naphthoquinones and Their Analogs against Psoroptes cuniculi. Sci. Rep. 2018, 8, 1609. [CrossRef]
[PubMed]
63. Keenan, M.; Abbott, M.J.; Diao, H.; Wang, Z.; Best, W.M.; Keatley, S.K.; Charman, S.A.; Ryan, E.; Ioset, J.
Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi.
Future Med. Chem. 2013, 5, 1733–1752. [CrossRef] [PubMed]
64. Meyer, J.M.; Ejendal, K.F.K.; Avramova, L.V.; Garland-Kuntz, E.E.; Giraldo-Calderón, G.I.; Brust, T.F.; Watts, V.J.;
Hill, C.A. A “genome-to-lead” approach for insecticide discovery: Pharmacological characterization and
screening of Aedes aegypti D1-like dopamine receptors. PLoS Negl. Trop. Dis. 2012, 6. [CrossRef] [PubMed]
65. Moraes, J.; Galina, A.; Alvarenga, P.H.; Rezende, G.L.; Masuda, A.; da Silva Vaz, I., Jr.; Logullo, C. Glucose
metabolism during embryogenesis of the hard tick Boophilus microplus. Comp. Biochem. Physiol. A Mol.
Integr. Physiol. 2007, 146, 528–533. [CrossRef] [PubMed]
66. Rosario-Cruz, R.; Almazan, C.; Miller, R.J.; Dominguez-Garcia, D.I.; Hernandez-Ortiz, R.; de la Fuente, J.
Genetic basis and impact of tick acaricide resistance. Front. Biosci. 2009, 14, 2657–2665. [CrossRef]
67. Kempf, J.G.; Jung, J.Y.; Ragain, C.; Sampson, N.S.; Loria, J.P. Dynamic requirements for a functional protein
hinge. J. Mol. Biol. 2007, 368, 131–149. [CrossRef] [PubMed]
68. Minini, L.; Alvarez, G.; Gonzalez, M.; Cerecetto, H.; Merlino, A. Molecular docking and molecular dynamics
simulation studies of Trypanosoma cruzi triosephosphate isomerase inhibitors. Insights into the inhibition
mechanism and selectivity. J. Mol. Gr. Model. 2015, 58, 40–49. [CrossRef] [PubMed]
69. Rodriguez-Romero, A.; Hernandez-Santoyo, A.; del Pozo Yauner, L.; Kornhauser, A.; Fernandez-Velasco, D.A.
Structure and inactivation of triosephosphate isomerase from Entamoeba histolytica. J. Mol. Biol. 2002, 322,
669–675. [CrossRef]
70. Feyereisen, R. Evolution of insect P450. Biochem. Soc. Trans. 2006, 34, 1252–1255. [CrossRef] [PubMed]
Vet. Sci. 2018, 5, 74 19 of 19
71. Jiang, G.; Zhang, Y.; Chen, F.; Li, J.; Li, X.; Yue, J.; Liu, H.; Li, H.; Ran, C. Differential Analysis of the
Cytochrome p450 Acaricide-Resistance Genes in Panonychus citri (Trombidiformes: Tetranychidae) Strains.
Fla. Entomol. 2015, 98, 318–329. [CrossRef]
72. Ramasamy, R.; Yan, S.F.; Schmidt, A.M. Methylglyoxal comes of AGE. Cell 2006, 124, 258–260. [CrossRef]
[PubMed]
73. Ahmed, N.; Battah, S.; Karachalias, N.; Babaei-Jadidi, R.; Horanyi, M.; Baroti, K.; Hollan, S.; Thornalley, P.J.
Increased formation of methylglyoxal and protein glycation, oxidation and nitrosation in triosephosphate
isomerase deficiency. Biochim. Biophys. Acta 2003, 1639, 121–132. [CrossRef] [PubMed]
74. Merlino, A.; Benitez, D.; Chavez, S.; Da Cunha, J.; Hernández, P.; Tinoco, L.W.; Campillo, N.E.;
Páez, J.A.; Cerecetto, H.; González, M. Development of second generation amidinohydrazones, thio- and
semicarbazones as Trypanosoma cruzi-inhibitors bearing benzofuroxan and benzimidazole 1,3-dioxide core
scaffolds. Medchemcomm 2010, 1, 216–228. [CrossRef]
75. Ross, F.; Hernandez, P.; Porcal, W.; Lopez, G.V.; Cerecetto, H.; Gonzalez, M.; Basika, T.; Carmona, C.; Flo, M.;
Maggioli, G.; et al. Identification of thioredoxin glutathione reductase inhibitors that kill cestode and
trematode parasites. PLoS ONE 2012, 7, e35033. [CrossRef] [PubMed]
76. Cabrera, M.; Lavaggi, M.L.; Hernandez, P.; Merlino, A.; Gerpe, A.; Porcal, W.; Boiani, M.; Ferreira, A.;
Monge, A.; de Cerain, A.L.; et al. Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi
5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction.
Toxicol. Lett. 2009, 190, 140–149. [CrossRef] [PubMed]
77. Kessel, D.; Belton, J.G.; Belton, D.K.J.G. Effects of 4-Nitrobenzofurazans and Their N-Oxides on Synthesis of
Protein and Nucleic Acid by Murine Leukemia Cells Effects of 4-Nitrobenzofurazans and Their N-Oxides on
Synthesis of Protein and Nucleic Acid by Murine Leukemia Cells. Cancer Res. 1975, 35, 3735–3740. [PubMed]
78. Thompson, S.; Kellicutt, L. Mutagenicity of anti-cancer nitrobenzofuroxans. Mutat. Res. 1977, 48, 145–153.
[CrossRef]
79. Deridder, B.P.; Dixon, D.P.; Beussman, D.J.; Edwards, R.; Goldsbrough, P.B. Induction of glutathione
S-transferases in Arabidopsis by herbicide safeners. Plant Physiol. 2002, 130, 1497–1505. [CrossRef] [PubMed]
80. Wang, L.; Zhang, Y.-Y.; Wang, L.; Liu, F.; Cao, L.-L.; Yang, J.; Qiao, C.; Ye, Y. Benzofurazan derivatives as
antifungal agents against phytopathogenic fungi. Eur. J. Med. Chem. 2014, 80, 535–542. [CrossRef] [PubMed]
81. Leyva, E.; Leyva, S.; González-Balderas, R.M.; De Loera, D.; Jiménez-Cataño, R. Fast preparation of
benzofuroxans by microwave-assisted pyrolysis of o-nitrophenyl azides. Mendeleev Commun. 2013, 23,
217–218. [CrossRef]
82. Kumar, S.; Sharma, A.K.; Nagar, G.; Ghosh, S. Determination and establishment of discriminating
concentrations of malathion, coumaphos, fenvalerate and fipronil for monitoring acaricide resistance in ticks
infesting animals. Ticks Tick. Borne Dis. 2015, 6, 383–387. [CrossRef] [PubMed]
83. Wang, X.; Martínez, M.A.; Wu, Q.; Ares, I.; Martínez-Larrañaga, M.R.; Anadón, A.; Yuan, Z. Fipronil
insecticide toxicology: Oxidative stress and metabolism. Crit. Rev. Toxicol. 2016, 46, 876–899. [CrossRef]
[PubMed]
84. Pardío, V.T.; Ibarra, N.D.J.; Waliszewski, K.N.; López, K.M. Effect of coumaphos on cholinesterase activity,
hematology, and biochemical blood parameters of bovines in tropical regions of Mexico. J. Environ. Sci. Heal.
Part B Pestic. Food Contam. Agric. Wastes 2007, 42, 359–366. [CrossRef] [PubMed]
Sample Availability: Samples of the studied compounds are available from the authors.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
